Harbor ETF Trust Harbor Health Care ETF (ARCA: MEDI)

Latest news for Harbor ETF Trust Harbor Health Care ETF (ARCA:MEDI)

Healthcare

Basic Materials

The Fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the Fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry (health care companies). Health care companies may include, for example, manufacturers of health care equipment and supplies, health care services providers, pharmaceutical companies, biotechnology and life sciences companies, and suppliers of technologies for use by health care companies. The Fund may invest in issuers of all market capitalizations, including larger, established issuers and newer companies with little or no current revenues. The Fund may invest in foreign securities (including through investment in depositary receipts), with such investments typically representing less than 35% of the Funds net assets.

Ascendis Pharma A/S

Abbvie Inc - Eln

Legend Biotech Corp

Pfizer, Inc.

Masimo Corp

Dexcom Inc.

Unitedhealth Group Inc.

Sanofi, Adr

Lantheus Holdings Inc

Vaxcyte Inc

Harbor Health Care ETF

Joe Biden

Biotech

Sector ETFs

Health Care

Movers

ETFs

General

First Trust Morningstar Dividend Leaders Index Fund

MEDI

MRNA

NVAX

RDIV

FTHX

Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.

COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch

Harbor ETF Trust Harbor Health Care ETF

Media Network - United States Dollar

MEDIPHARM LABS CORP by Medipharm Labs Corporation

MediPharm Labs Corp

MEDIA CENTRAL CORP INC by Media Central Corporation Inc.

MEDIA TEK INC by Media Tek Inc.

MEDIABAY INC by MediaBay, Inc.

MEDIASET ESPANA COMMS ORD by Mediaset Espana Communicacion, S.A.

MEDICAL DATA VSION CO LTD by MEDICAL DATA VISION CO LTD.

MEDICENNA THERAPEUTICS CORP COM

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Technologies Inc

MediBloc

MediWound Ltd

MEDIXALL GROUP INC by MediXall Group, Inc.

MediXall Group Inc

Media 100 Inc

Media Do Co Ltd

MEDIA PAL HOLDINGS CORP by Media Pal Holdings, Corp.

Media Pal Holdings Corp

MEDIA SENTIMENT INC by Media Sentiment, Inc.

Media Sentiment Inc

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

Media Way Corp

MediaAlpha Inc

Mediaco Holding Inc. - Class A Common Stock

MediaCo Holding Inc

MediaG3 Inc

MEDIATECHNICS CORP by MediaTechnics Corp.

MediaTechnics Corp

MediaTek Inc

MediaValet Inc

Mediaset Espana Comunicacion SA ADR

MEDIBANK PRIVATE UNSP/ADR by MEDIBANK PRIVATE LTD

Medibank Pvt Ltd

MEDIBANK PRIVATE LTD by MEDIBANK PRIVATE LTD

MEDICAL CANNABIS PYMT SL by Medical Cannabis Payment Solutions

Medical Cannabis Payment Solutions Inc

MEDICAL CARE TECHS INC by Medical Care Technologies Inc.

Medical Care Technologies Inc

MEDICAL CONNECTIONS HLDGS by Medical Connections Holdings, Inc.

Medical Connections Holdings Inc

MEDICAL DEV INTL LTD ORD by Medical Developments International Ltd.

Medical Developments International Ltd

MEDICAL FACILITIES CORP by Medical Facilities Corp.

Medical Facilities Corp

MEDICAL IMAGING CORP by Medical Imaging Corp.

Medical Imaging Corp

MEDICAL INTL TECH INC by Medical International Technology, Inc.

Medical International Technology Inc

MEDICAL MARIJUANA INC by Medical Marijuana, Inc.

Medical Marijuana Inc

MEDICAL MEDIA TV INC by Medical Media Television, Inc.

Medical Media TV Inc

Medical Properties Trust, Inc. common stock

Medical Properties Trust Inc

MEDICAL SVCS INTL INC by Medical Services International Inc.

Medical Services International Inc

MEDICAL SUPPLY INTL USA by Medical Supply International USA, Inc.

Medical Supply International USA Inc

MEDICAL SYS NETWK CO LTD by Medical System Network Co., Ltd.

Medical System Network Co Ltd

Medicale Corp

MEDICAN ENTERPRISES INC by Medican Enterprises Inc

Medican Enterprises Inc

MEDICENNA THERA CORP by Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp

MediciNova Inc

MEDICINE MAN TECH INC by Medicine Man Technologies Inc.

Medicine Man Technologies Inc

Mediclinic International PLC ADR

Medicover AB

Medicure Inc

Medicus Pharma Limited COM

Medicus Pharma Limited COM NEW

Medicus Pharma Ltd

Medicus Pharma Ltd. - Warrant

Medies

Medifast Inc

Medigene AG

Medigene AG Namen-Akt. nach Kapitalherabsetzung

Medikit Co Ltd

MEDINAH MINERALS INC by Medinah Minerals, Inc.

Medinah Minerals Inc

Medincell SA

Medinotec Inc

MEDIOBANCA SPA UNSP/ADR by MedioBanca SpA

Mediobanca SpA

Medios AG

MEDIPAL HLDGS UNSP/ADR by Medipal Holdings Corp.

Medipal Holdings Corp

MEDIPAL HOLDINGS CRP ORD by Medipal Holdings Corp.

Medirect Latino Inc

MEDITE CANCER DIAGNOSTICS by Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Medivolve Inc

Earnings

Earnings Beats

News

NBBK

NB Bancorp Q4 2024 EPS $0.34 Beats $0.32 Estimate

<p><strong>QCR Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>QCR Hldgs beat estimated earnings by 10.0%, reporting an EPS of $1.93 versus an estimate of $1.76.</p>
<p>Revenue was up $5.47 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.26 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at QCR Hldgs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.52</td>
<td>1.40</td>
<td>1.30</td>
<td>1.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.78</td>
<td>1.73</td>
<td>1.59</td>
<td>1.97</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>61.47M</td>
<td>65.25M</td>
<td>63.77M</td>
<td>58.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>59.72M</td>
<td>56.16M</td>
<td>54.70M</td>
<td>55.74M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for QCR Hldgs <a href="https://www.benzinga.com/quote/QCRH/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QCRH

QCR Hldgs Earnings Analysis: Q4 Recap

<p><strong>Triumph Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:07 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Triumph Financial missed estimated earnings by -48.0%, reporting an EPS of $0.13 versus an estimate of $0.25.</p>
<p>Revenue was down $2.59 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.01 which was followed by a 5.0% increase in the share price the next day.</p>
<p>Here's a look at Triumph Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.18</td>
<td>0.22</td>
<td>0.34</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.08</td>
<td>0.14</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>107.30M</td>
<td>104.08M</td>
<td>106.01M</td>
<td>106.85M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.20M</td>
<td>105.08M</td>
<td>101.03M</td>
<td>106.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Triumph Financial <a href="https://www.benzinga.com/quote/TFIN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TFIN

Triumph Financial Earnings Analysis: Q4 Recap

<p>Towne Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOWN#NASDAQ">TOWN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.48 by 14.58 percent. This is a 30.95 percent increase over earnings of $0.42 per share from the same period last year.  The company reported quarterly sales of $177.16 million which beat the analyst consensus estimate of $170.78 million by 3.74 percent.  This is a 13.90 percent increase over sales of $155.55 million the same period last year.</p>


TOWN

Towne Bank Q4 Adj $0.55 Beats $0.48 Estimate, Sales $177.16M Beat $170.78M Estimate

<p>The earnings results for <strong>SL Green Realty</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>SL Green Realty beat estimated earnings by 18.0%, reporting an EPS of $1.81 versus an estimate of $1.53.</p>
<p>Revenue was up $7.69 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company missed on EPS by $0.07, resulting in a 3.0% increase change in the share price the following day.</p>
<p>Here's a look at SL Green Realty's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.20</td>
<td>1.60</td>
<td>2.16</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.13</td>
<td>2.05</td>
<td>3.07</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>136.66M</td>
<td>149.28M</td>
<td>152.67M</td>
<td>161.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>139.62M</td>
<td>135.56M</td>
<td>128.20M</td>
<td>131.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SL Green Realty <a href="https://www.benzinga.com/quote/SLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SL Green Realty Q4 Earnings Assessment

<p>The Q4 earnings report for <strong>Hexcel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) was released on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hexcel missed estimated earnings by 0.0%, reporting an EPS of $0.52 versus an estimate of $0.52.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Hexcel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.46</td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.47</td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>456.90M</td>
<td>483.36M</td>
<td>473.78M</td>
<td>471.69M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>456.50M</td>
<td>500.40M</td>
<td>472.30M</td>
<td>457.50M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hexcel <a href="https://www.benzinga.com/quote/HXL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Hexcel Q4 Earnings

<p>The earnings results for <strong>Plexus</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) for Q1 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Plexus beat estimated earnings by 9.0%, reporting an EPS of $1.73 versus an estimate of $1.59.</p>
<p>Revenue was down $6.88 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.3 in the last quarter, resulting in a 7.000000000000001% increase share price change the following day.</p>
<p>Here's a look at Plexus's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.55</td>
<td>1.30</td>
<td>0.87</td>
<td>1.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.85</td>
<td>1.45</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.01B</td>
<td>981.25M</td>
<td>950.83M</td>
<td>987.63M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.05B</td>
<td>961.00M</td>
<td>967.00M</td>
<td>983.00M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Plexus management provided guidance for Q2 2025, expecting earnings between $1.46 and $1.61 per share.</p>
<p>To track all earnings releases for Plexus <a href="https://www.benzinga.com/quote/PLXS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLXS

Plexus: Q1 Earnings Insights

<p><strong>National Bank Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>National Bank Holdings beat estimated earnings by 12.0%, reporting an EPS of $0.86 versus an estimate of $0.77.</p>
<p>Revenue was up $600 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 8.0% increase share price change the next day.</p>
<p>Here's a look at National Bank Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.75</td>
<td>0.74</td>
<td>0.76</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.68</td>
<td>0.82</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>104.59M</td>
<td>102.96M</td>
<td>103.68M</td>
<td>103.96M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.04M</td>
<td>97.60M</td>
<td>101.72M</td>
<td>107.23M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for National Bank Holdings <a href="https://www.benzinga.com/quote/NBHC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NBHC

Earnings Breakdown: National Bank Holdings Q4

<p><strong>CACI International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) reported its Q2 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>CACI International beat estimated earnings by 13.0%, reporting an EPS of $5.95 versus an estimate of $5.25.</p>
<p>Revenue was up $266.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.86 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at CACI International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>5.07</td>
<td>5.93</td>
<td>5.63</td>
<td>4.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>5.93</td>
<td>6.61</td>
<td>5.74</td>
<td>4.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.92B</td>
<td>1.93B</td>
<td>1.86B</td>
<td>1.84B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>2.04B</td>
<td>1.94B</td>
<td>1.83B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>CACI International management provided guidance for FY 2025, expecting earnings between $23.87 and $24.76 per share.</p>
<p>To track all earnings releases for CACI International <a href="https://www.benzinga.com/quote/CACI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CACI

CACI International Earnings Review: Q2 Summary

<p><strong>Third Coast Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Third Coast Bancshares beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.79 versus an estimate of $0.69.</p>
<p>Revenue was up $6.82 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat on EPS by $0.2 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at Third Coast Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.57</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.63</td>
<td>0.61</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>41.67M</td>
<td>41.13M</td>
<td>39.30M</td>
<td>38.13M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>42.90M</td>
<td>41.75M</td>
<td>40.42M</td>
<td>39.49M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Third Coast Bancshares <a href="https://www.benzinga.com/quote/TCBX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TCBX

Third Coast Bancshares Q4 Earnings Assessment

<p>The earnings results for <strong>Wesbanco</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Wesbanco beat estimated earnings by 28.999999999999996%, reporting an EPS of $0.71 versus an estimate of $0.55.</p>
<p>Revenue was up $8.75 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.05, resulting in a 1.0% drop change in the share price the following day.</p>
<p>Here's a look at Wesbanco's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.53</td>
<td>0.55</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>0.49</td>
<td>0.56</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>120.74M</td>
<td>126.11M</td>
<td>116.83M</td>
<td>116.77M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>121.14M</td>
<td>116.59M</td>
<td>113.97M</td>
<td>117.76M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Wesbanco <a href="https://www.benzinga.com/quote/WSBC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WSBC

Wesbanco Earnings Analysis: Q4 Recap

<p><strong>Univest Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UVSP#NASDAQ">UVSP</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Univest Financial beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.65 versus an estimate of $0.57.</p>
<p>Revenue was up $5.42 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.09 which was followed by a 4.0% increase in the share price the next day.</p>
<p>Here's a look at Univest Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.51</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>0.61</td>
<td>0.60</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>73.20M</td>
<td>72.30M</td>
<td>72.20M</td>
<td>71.25M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>73.35M</td>
<td>72.01M</td>
<td>77.06M</td>
<td>71.38M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Univest Financial <a href="https://www.benzinga.com/quote/UVSP/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UVSP

Univest Financial Earnings Review: Q4 Summary

<p><strong>Equity Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:45 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Equity Bancshares beat estimated earnings by 13.0%, reporting an EPS of $1.04 versus an estimate of $0.92.</p>
<p>Revenue was up $62.24 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.32, resulting in a 2.0% increase change in the share price the following day.</p>
<p>Here's a look at Equity Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.92</td>
<td>0.85</td>
<td>-1.88</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.31</td>
<td>0.99</td>
<td>0.90</td>
<td>-1.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>56.09M</td>
<td>55.15M</td>
<td>52.81M</td>
<td>29.49M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>55.35M</td>
<td>55.43M</td>
<td>55.91M</td>
<td>-3M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Equity Bancshares <a href="https://www.benzinga.com/quote/EQBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EQBK

Earnings Breakdown: Equity Bancshares Q4

<p>Shares of solar stocks, including <strong>First Solar Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and <strong>SolarEdge Technologies, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) were volatile Wednesday as investors reacted to President Donald Trump&#8217;s newly signed <a href="https://www.benzinga.com/25/01/43109461/gold-miners-defense-stocks-shine-while-solar-tanks-following-trumps-day-1-actions">executive orders promoting </a>fossil fuels and reversing climate-focused policies.</p>
<p><strong>What To Know: </strong> The sell-off followed Trump's inauguration and his immediate signature on executive orders prioritizing oil and gas development over renewable energy initiatives.</p>
<p>According to<a href="https://www.nytimes.com/2025/01/20/climate/trump-emergency-oil-gas.html"> the New York Times</a>, his administration announced plans to withdraw from the Paris Agreement, expand fossil fuel drilling on public lands and waters, and eliminate regulatory support for electric vehicles and renewable energy projects. Trump also declared a national energy emergency aimed at accelerating fossil fuel production, further unsettling renewable energy investors.</p>
<p>The market&#8217;s response may reflect concerns over the new administration's shift in energy policy, which contrasts sharply with the pro-renewable initiatives under the previous Biden administration. Analysts believe this pivot could slow the growth of the renewable energy sector and significantly impact solar companies, contributing to the downward pressure on their stock prices.</p>
<p><strong>Price Action: </strong>First Solar&#8217;s stock closed Wednesday at $171.90, down 6.33%, and SolarEdge Technologies closed at $13.05, down 4.74%, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43144023/riot-stock-poised-break-out-consolidation-cycle">Options Corner: Riot Platforms Could Be Itching To Charge Higher</a></strong></li>
</ul>
<p><em>Photo: solarseven on Shutterstock</em>.</p>


Government

FSLR

SEDG

Solar Shares Are Volatile Today: What's Going On?

<p>CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 7.69 percent decrease over earnings of $0.39 per share from the same period last year.</p>


CVBF

CVB Financial Q4 EPS $0.36 Beats $0.34 Estimate

WIIM

BETR

Better Home & Finance shares are trading higher after the company announced a $25 million share repurchase program.

<p>Jean Madar, Chairman &amp; Chief Executive Officer of Interparfums, stated, "Our net sales in the final quarter of 2024 marked our best-ever fourth quarter performance, with quarterly sales growth of 10%, enabling us to achieve our 2024 sales goal of $1.45 billion."</p>
<p>Achieving the sales goal of $1.45 billion positions the Company to meet its full year 2024 earnings per diluted share target of $5.15, excluding a supplemental non-recurring, non-cash impairment charge of approximately $0.07 per diluted share, associated with trademarks.</p>


Guidance

IPAR

Interparfums Q4 Net Sales Up 10% To $362M, Est $361.807M

Macro Economic Events

Econ #s

Economics

API Weekly Crude Stock: 1M Barrel Build

<p><strong>Knight-Swift</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:02 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Knight-Swift beat estimated earnings by 9.0%, reporting an EPS of $0.36 versus an estimate of $0.33.</p>
<p>Revenue was down $67.72 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company beat on EPS by $0.02 in the previous quarter, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at Knight-Swift's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.28</td>
<td>0.20</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.24</td>
<td>0.12</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.91B</td>
<td>1.83B</td>
<td>1.82B</td>
<td>1.97B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.88B</td>
<td>1.85B</td>
<td>1.82B</td>
<td>1.93B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Knight-Swift management provided guidance for Q2 2025, expecting earnings between $0.46 and $0.5 per share.</p>
<p>To track all earnings releases for Knight-Swift <a href="https://www.benzinga.com/quote/KNX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Knight-Swift: Q4 Earnings Insights

<p><strong>Fourth Quarter and Full Year 2024 Preliminary Results</strong></p>
<p>For the fourth quarter 2024, Concentra expects to report:</p>
<ul>
<li>Revenue of $465.0 million, an increase of 5.5% over Q4 2023</li>
<li>Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023</li>
<li>Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023</li>
<li>Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023</li>
<li>Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023</li>
<li>Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023</li>
<li>Total occupational health centers of 552, compared to 544 at end of Q4 2023</li>
<li>Total onsite health clinics of 157, compared to 150 at end of Q4 2023</li>
</ul>
<p>For full year 2024, Concentra expects to report:</p>
<ul>
<li>Revenue of $1,900.2 million, an increase of 3.4% over FY 2023</li>
<li>Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023</li>
<li>Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023</li>
<li>Cash balance of $183.3 million and net leverage ratio of approximately 3.5x</li>
<li>Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023</li>
<li>Revenue per Visit of $141.30, an increase of 4.5% over FY 2023</li>
<li>Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023</li>
</ul>


Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4

MedImmune

<p>More than half of the states in the U.S. are experiencing <a href="https://www.benzinga.com/24/07/39829417/biden-gets-covid-19-takes-a-fiesty-dig-at-tesla-ceo-im-sick-of-elon-musk-and-his-rich-buddies-trying">significant Covid-19 activity </a>in wastewater, and President<strong> Joe Biden </strong>remains in isolation after announcing Wednesday he caught the virus for the third time.</p>



<p>Twenty-six states are reporting either &#8220;high&#8221; or &#8220;very high&#8221; levels of the virus at various sites, according to the latest<a href="https://www.cdc.gov/nwss/rv/COVID19-currentlevels.html"> data </a>from the Centers for Disease Control and Prevention.</p>



<p>States with the highest levels include Arkansas, California, Florida, Maryland, Nevada, Oregon and Texas. </p>



<p>The Biden administration no longer considers Covid-19 a public health emergency and instead treats it as a routine respiratory virus to be prevented through an annual vaccination campaign, the Washington Post <a href="https://www.washingtonpost.com/health/2024/07/18/biden-covid-summer-wave-symptoms-flirt-variant/">reported</a>.</p>



<p><strong>Also Read: <a href="https://www.benzinga.com/general/biotech/24/07/39823289/european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-">European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen&#8217;s Reappointment</a></strong></p>



<p>Biden is staying at his Rehoboth Beach home in Delaware while continuing to perform presidential duties.</p>



<p><strong>Vaccine Stocks To Watch: Novovax, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), <strong>Moderna, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and <strong>Pfizer Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) are all making new Covid vaccines that should be available before the end of September, the New York Times <a href="https://www.nytimes.com/article/long-covid-vaccine.html">reported</a>.</p>



<p>The Novavax vaccine will target JN.1, the variant that was prominent in the winter and spring.</p>



<p>Pfizer and Moderna are developing shots aimed at KP.2, which accounts for about one in four new cases. Two related variants, KP.3 and LB.1, are the culprint behind more than half of new cases, the Times said. </p>



<p>All three variants are descendants of JN.1, so each of the vaccines is expected to be effective against them.</p>



<p><strong>NVAX, MRNA, PFE Price Action:</strong> Novovax shares were down 5.7% to $14.94 late in Thursday&#8217;s session. Moderna was down 2.16% to $121.37. Pfizer is down 1.07% at $29.70. </p>



<p>Exchange-traded funds that hold shares of Pfizer, which has the largest market capitalization of the group of vaccine developers at $169 billion, declined in Thursday afternoon trading. </p>



<ul>
<li><strong>First Trust Nasdaq Pharmaceuticals ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHX#NASDAQ">FTHX</a>) fell 0.35%.</li>



<li><strong>First Trust Morningstar Dividend Leaders Index Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDL#NYSE">FDL</a>) slipped 0.69%.</li>



<li><strong>Invesco Pharmceuticals ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) slid 0.55%.</li>



<li><strong>Harbor Health Care ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEDI#NYSE">MEDI</a>) lost 0.33%.</li>



<li><strong>Invesco S&amp;P Ultra dividend Revenue ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDIV#NYSE">RDIV</a>) declined 0.66%.</li>
</ul>



<p><strong>Read Now: </strong></p>



<ul>
<li><strong><a href="https://www.benzinga.com/news/24/07/39770202/moderna-regeneron-pharmaceuticals-and-2-other-stocks-insiders-are-selling">Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling</a></strong></li>
</ul>



<p><em>Photo via Shutterstock. </em></p>

Comments

Harbor ETF Trust Harbor Health Care ETF

News

Latest news for Harbor ETF Trust Harbor Health Care ETF (ARCA:MEDI)

Thursday, July 18, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga